Literature DB >> 25396216

Small Molecule PAI-1 Functional Inhibitor Attenuates Vascular Smooth Muscle Cell Migration and Survival: Implications for the Therapy of Vascular Disease.

Tessa M Simone1, Paul J Higgins1.   

Abstract

Entities:  

Keywords:  PAI-1; SERPIN; Vascular disease; apoptosis; migration; pericellular proteolysis; tiplaxtinin; vascular smooth muscle cells

Year:  2014        PMID： 25396216      PMCID： PMC4226527          DOI： 10.1016/j.nhtm.2014.08.003

Source DB:  PubMed          Journal:  New Horiz Transl Med        ISSN： 2307-5023


× No keyword cloud information.
  40 in total

1.  The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression.

Authors:  Nhan L Tran; Wendy S McDonough; Benjamin A Savitch; Thomas F Sawyer; Jeffrey A Winkles; Michael E Berens
Journal:  J Biol Chem       Date:  2004-12-16       Impact factor: 5.157

2.  Apoptosis participates in cellularity regulation during rat aortic intimal thickening.

Authors:  M L Bochaton-Piallat; F Gabbiani; M Redard; A Desmoulière; G Gabbiani
Journal:  Am J Pathol       Date:  1995-05       Impact factor: 4.307

3.  Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death: implications for vascular disease and therapy.

Authors:  M Sata; T Suhara; K Walsh
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-02       Impact factor: 8.311

4.  Tiplaxtinin impairs nutritionally induced obesity in mice.

Authors:  H Roger Lijnen; Marie-Christine Alessi; Liesbeth Frederix; Désiré Collen; Irène Juhan-Vague
Journal:  Thromb Haemost       Date:  2006-12       Impact factor: 5.249

5.  Bcl-2 and Bcl-XL serve an anti-inflammatory function in endothelial cells through inhibition of NF-kappaB.

Authors:  A Z Badrichani; D M Stroka; G Bilbao; D T Curiel; F H Bach; C Ferran
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

Review 6.  The 'PAI-1 paradox' in vascular remodeling.

Authors:  Isabel Diebold; Damir Kraicun; Steve Bonello; Agnes Görlach
Journal:  Thromb Haemost       Date:  2008-12       Impact factor: 5.249

7.  Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease.

Authors:  B O Olofsson; G Dahlén; T K Nilsson
Journal:  Eur Heart J       Date:  1989-01       Impact factor: 29.983

8.  Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.

Authors:  J Schneiderman; M S Sawdey; M R Keeton; G M Bordin; E F Bernstein; R B Dilley; D J Loskutoff
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

9.  Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization.

Authors:  Hassan Elokdah; Magid Abou-Gharbia; James K Hennan; Geraldine McFarlane; Cheryl P Mugford; Girija Krishnamurthy; David L Crandall
Journal:  J Med Chem       Date:  2004-07-01       Impact factor: 7.446

10.  Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis.

Authors:  H C Kwaan; J Wang; K Svoboda; P J Declerck
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.